The Biology of Leukotrienes: Potent Bronchoconstrictors and Inflammatory Mediators

Leukotrienes are a family of eicosanoid inflammatory mediators produced from arachidonic acid by the action of the enzyme 5-lipoxygenase (5-LOX). Primarily synthesized by leukocytes—including mast cells, eosinophils, and neutrophils—leukotrienes are among the most potent biological molecules known, exerting significant effects on vascular permeability and smooth muscle contraction at extremely low concentrations.

The Biosynthetic Pathway

The production of leukotrienes begins when arachidonic acid is released from cell membranes by phospholipase A2. The enzyme 5-LOX, in conjunction with the 5-lipoxygenase-activating protein (FLAP), then converts arachidonic acid into the unstable intermediate leukotriene A4 (LTA4). Depending on the cell type and the enzymes present, LTA4 is then converted into either leukotriene B4 (LTB4) or the cysteinyl-leukotrienes (LTC4, LTD4, and LTE4).

LTB4: The Chemotactic Signal

LTB4 is a powerful chemoattractant that recruits and activates neutrophils and other immune cells to the site of inflammation. It promotes the adhesion of these cells to the vascular endothelium and stimulates the release of lysosomal enzymes and reactive oxygen species, thereby amplifying the immune response. Dysregulated LTB4 production is implicated in various chronic inflammatory conditions, including rheumatoid arthritis and inflammatory bowel disease.

Cysteinyl-Leukotrienes: The Bronchoconstrictors

The cysteinyl-leukotrienes (CysLTs) are primarily known for their role in the pathogenesis of asthma and allergic rhinitis. They are incredibly potent bronchoconstrictors—thousands of times more powerful than histamine—causing significant narrowing of the airways. In addition to muscle contraction, CysLTs increase mucus secretion and promote vascular leakage, leading to the airway edema and obstruction characteristic of an asthma attack.

Therapeutic Targeting of Leukotrienes

The realization of the central role of leukotrienes in respiratory diseases has led to the development of several classes of drugs. Leukotriene receptor antagonists (LTRAs), such as montelukast and zafirlukast, block the action of CysLTs at their receptors, while 5-LOX inhibitors, such as zileuton, prevent their synthesis entirely. These medications have become mainstay treatments for the long-term management of asthma, providing relief for patients who may not respond adequately to inhaled corticosteroids alone.